Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrilynX: Debio 1143 plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
2020-000377-25Phase 3Completed
- Sponsor
- Debiopharm
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Debio 1143 + platinum-based chemoradiotherapy with Placebo + platinum-based chemoradiotherapy (2 arms). Primary endpoint: Event-free survival. Started Jul 2020; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-000377-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000377-25.